![](https://cdn.sanity.io/images/0vv8moc6/onclive/1ebfd050ac1b8b618b6936a72e2aa4023f00674b-200x200.jpg?fit=crop&auto=format)
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer
Although assays measuring molecular residual disease (MRD) have demonstrated analytical validity, data from prospective trials are necessary to assess the clinical utility of using MRD and circulating tumor DNA (ctDNA) status to inform real-world treatment …